EPHB2 and colorectal carcinoma: Based on the high frequency of concurrent APC and KRAS mutations and their strong cooperative interaction, therapies targeting both the WNT/beta-catenin and RAS/ERK pathways would therefore be the ideal treatments for human CRC [171].